Use of CD23 antagonists for the treatment of neoplastic disorders

Details for Australian Patent Application No. 2002237972 (hide)

International Classifications

Event Publications

20 February 2003 Application Open to Public Inspection

Published as AU-B-2002237972

4 November 2004 Change of Name(s) of Applicant(s), Section 104

Idec Pharmaceuticals Corporation The name of the applicant has been changed to Biogen Idec Inc.

29 November 2007 Application Accepted

Published as AU-B-2002237972

17 April 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

22 May 2008 Section 223 Application Allowed

Biogen Idec Inc. The time in which to pay the acceptance fee has been extended to 29 Apr 2008. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000 2003

29 May 2008 Standard Patent Sealed

25 August 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.